Contrasting C4 Therapeutics (NASDAQ:CCCC) & Arcturus Therapeutics (NASDAQ:ARCT)

Arcturus Therapeutics (NASDAQ:ARCT) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Arcturus Therapeutics and C4 Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-68.35%	-28.68%	-21.05%
C4 Therapeutics	-395.51%	-64.40%	-38.69%

Risk and Volatility

Arcturus Therapeutics has a beta of 2.24, meaning that its share price is 124% more volatile than the S&P 500. Comparatively, C4 Therapeutics has a beta of 2.93, meaning that its share price is 193% more volatile than the S&P 500.

Institutional and Insider Ownership

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are owned by institutional investors. 16.6% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 8.7% of C4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Arcturus Therapeutics and C4 Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1	4	8	0	2.54
C4 Therapeutics	1	2	5	0	2.50

Arcturus Therapeutics currently has a consensus price target of $34.00, indicating a potential upside of 351.53%. C4 Therapeutics has a consensus price target of $7.25, indicating a potential upside of 237.21%. Given Arcturus Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcturus Therapeutics is more favorable than C4 Therapeutics.

Valuation & Earnings

This table compares Arcturus Therapeutics and C4 Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$152.31 million	1.40	-$80.94 million	($2.46)	-3.06
C4 Therapeutics	$30.11 million	6.92	-$105.32 million	($1.67)	-1.29

Arcturus Therapeutics has higher revenue and earnings than C4 Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Arcturus Therapeutics beats C4 Therapeutics on 10 of the 14 factors compared between the two stocks.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.